Treatment of Esophageal Candidiasis
Diagnosis
- The patient's presentation is consistent with esophageal candidiasis, characterized by linear yellow to white plaques on esophageal mucosa seen on EGD, difficulty swallowing, and HIV infection, a major risk factor, as recommended by the Infectious Diseases Society of America 1
- HIV infection is a major risk factor for esophageal candidiasis, as stated by the Centers for Disease Control and Prevention 1, 2
First-line Treatment
- The American College of Physicians recommends oral fluconazole 200-400 mg daily for 14-21 days as the first-line treatment for esophageal candidiasis, with strong recommendation and high-quality evidence 1, 2, 3
- Fluconazole is superior to ketoconazole and comparable to itraconazole solution, with most patients showing improvement within 7 days of starting therapy, as reported by the Infectious Diseases Society of America 3
Alternative Options
- The Infectious Diseases Society of America recommends intravenous fluconazole 400 mg daily as an alternative option for patients who cannot tolerate oral therapy 1, 3
- Echinocandins, such as micafungin, caspofungin, and anidulafungin, are effective alternative options for patients who cannot tolerate azoles, as stated by the Centers for Disease Control and Prevention 1, 3
Prevention of Recurrence
- The Centers for Disease Control and Prevention recommends chronic suppressive therapy with fluconazole 100-200 mg three times weekly to prevent recurrence of esophageal candidiasis 1, 3
- Antiretroviral therapy is strongly recommended to reduce recurrence risk, as reported by the MMWR Recommendations and Reports 4
Monitoring
- The Infectious Diseases Society of America recommends assessing clinical response within 7 days and monitoring for adverse effects of fluconazole, including transaminase elevations, as stated by the Clinical Infectious Diseases journal 3, 4
- Completing the full treatment course is essential, even if symptoms resolve quickly, as recommended by the American College of Physicians 3